

HHS Expands Access to Treatment for OUD by Eliminating X-Waiver Requirement for DEA-Registered Physicians



In a historic move, the U.S. Dept. of Health and Human Services announced it will publish guidelines to increase access to MOUD by exempting physicians from certain certification requirements to prescribe buprenorphine for OUD. This applies to physicians who are located in the states they are authorized to practice medicine, and there is still a limitation of treating no more than 30 patients at any one time (this limit is NOT applicable to hospital-based physicians, including emergency department physicians). This is a big first step in allowing all DEA-registered physicians the ability to prescribe buprenorphine. For more information, click below.

[Click for the Article](#)



Substance Use Disorders and Telehealth in the COVID-19 Pandemic Era: A New Outlook

This is a review article of the available literature discussing the use of telehealth interventions in the treatment of SUDs, offering recommendations on the safe and effective implementation of those strategies.

[Click for the Article](#)

MAT Lunch Hour: Advocacy for Harm Reduction in Substance Use Disorders

Join us for the next MAT Lunch Hour to network and collaborate.



The next MAT lunch hour will feature **Wesley McWhite, Policy and Development Manager with Hyacinth AIDS Foundation**, who will be joining us to present on advocacy in the harm reduction and substance use space in New Jersey, including Harm Reduction Center expansion and HIV decriminalization legislation.

All are welcome!

Next Forum: Wednesday, January 20th, 12pm-1pm

[Register Here](#)

Sustaining an Effective MOUD Practice



PCSS-X is a project within PCSS that provides implementation technical assistance to healthcare organizations and providers for the use and/or expansion of substance use disorder (SUD) treatment services, including medications for opioid use disorder (MOUD). This program is free and you are welcome to participate in any of the sessions.

Next Session: Thursday, January 21st, 3pm-4pm

Objectives: This session will discuss key considerations for patient initiation (induction) and on-going visits, including lab guidelines. It will additionally address the clinical management of patients with continued opioid use, poly-substance use, and comorbid mental health conditions.

[Register Here](#)

The Evidence Behind the Low-Barrier MOUD Approach



The COEs are leading biweekly, interactive virtual educational sessions on MAT and continuous quality improvement topics. Register below for the ECHO series and to receive free CE credits.

First 2021 ECHO Session: Friday, Feb 5th, 12pm-1pm

Objectives: Participants will be able to:

- Define low barrier MOUD
- Identify the barriers to a low-threshold approach to MOUD
- Understand the seven principles of low barrier MOUD
- Utilize an evidence-based approach to buprenorphine

[Register Here](#)

OBAT Navigator Trainings and Events

Visit the **NEW** Camden Coalition OBAT homepage to find out more information on, and to register for, the Patient Navigator Trainings and Navigator Support Events.

OBAT Navigator Trainings: Four-part webinar series focusing on how to support patient's goals and priorities, utilizing best practices in connecting patients to behavioral health and social service resources.

Next Training: Tuesdays from March 16th-April 6th, 1pm-4pm

Navigator Support Events: Ongoing opportunity occurring every two months for OBAT navigators to continue learning




through de-identified patient cases, discussion of patient engagement strategies, and sharing of updated resources about relatives topics. This is similar to the MAT Lunch Hours but specific for patient navigators.

Next Event: Friday, February 5th, 12pm-1pm

[Click for the Homepage](#)

Has the Opioid Crisis Played a Role in Psychostimulant-Overdose Mortality in States across the US?



The last issue of the newsletter shared an article that rationalizes the overdose crisis as the polysubstance overdose death crisis. This article reviewed mortality data from the CDC. It found that significant increases in psychostimulant-involved overdose mortality rates were observed in a majority of states and was positively associated with increases in opioid prescribing rate in 2012, past-year prevalence of OUD from 2015-2018, and increases in drug overdose mortality during the earliest stages of the opioid crisis from 1999-2012. This further supports the idea that the US is facing an "epidemic of addiction" rather than just an "opioid epidemic."

[Click for the Article](#)

Treatment Strategies for Precipitated Withdrawal After Naloxone Rescue



This is an article written by Dr. Rachel Haroz from the Southern MAT Center of Excellence and colleagues that justifies the use of higher dose buprenorphine (16-24mg) to treat withdrawal and facilitate a quicker transition to buprenorphine maintenance compared to using traditional induction methods. If you have any questions, please email either the Northern or Southern COE.

[Click for the Article](#)

24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)
COE Websites: bit.ly/mat-coe AND snjmatcoe.org
Northern: coe@njms.rutgers.edu Southern: southernnjcoe@rowan.edu



